Activity Overview
This educational activity is an archive of the live presentation held on January 9, 2026.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational program is directed toward medical oncologists, pathologists, surgical oncologists, and other physicians involved in the management of GI cancers.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Analyze the latest evidence for currently available treatments used in the management of gastric, GEJ, and esophageal adenocarcinomas (GEAs)
- Evaluate emerging clinical trial data for targeted treatment strategies across GEAs
- Select appropriate treatment for patients with GEA based on tumor biomarkers and other individual patient, disease, and treatment considerations
- Implement strategies to mitigate and manage the AEs associated with targeted therapy for GEA
Manish A. Shah, MD, FASCO
Professor of Medicine
Bartlett Family Professor of Gastrointestinal Oncology
Chief, Solid Tumor Oncology
Weill Cornell Medicine
New York, NY
Syma Iqbal, MD
Associate Professor of Clinical Medicine
Medical Director, Inpatient Services, Norris Cancer Hospital
Medical Director for Ambulatory Services/Infusion Center
Associate Cancer Physician in Chief
Keck School of Medicine
University of Southern California
Los Angeles, CA
Haeseong Park, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Member, Gastrointestinal Cancer Center
Member, Center for Cancer Therapeutic Innovations
Dana-Farber Cancer Institute
Boston, MA
Full faculty information and disclosures are available by reviewing the program workbook, linked here.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.